KalVista Pharmaceuticals (KALV) EBITDA (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly EBITDA of -$61.3 million in Q3 2025, down 10.93% quarter-over-quarter from -$55.2 million in Q2 2025, and down 53.85% year-over-year from -$132.8 million in Q3 2024.
KalVista Pharmaceuticals' EBITDA history runs 12 years deep, the most recent figure standing at -$61.3 million for Q3 2025.
- In Q3 2025, EBITDA fell 53.85% year-over-year to -$61.3 million; the TTM figure through Jul 2025 stood at -$198.4 million (down 39.98% YoY), while the FY2025 annual figure was -$185.2 million, down 45.72% from the prior year.
- EBITDA came in at -$61.3 million for Q3 2025 at KalVista Pharmaceuticals, down from -$55.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$9.4 million in Q1 2021 to a low of -$61.3 million in Q3 2025.
- A 5-year average of -$29.3 million and a median of -$25.4 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA tumbled 146.67% in 2022 and increased 15.46% in 2023, its largest moves.
- KalVista Pharmaceuticals' EBITDA stood at -$19.9 million in 2021, then slipped by 17.87% to -$23.4 million in 2022, then declined by 20.45% to -$28.2 million in 2023, then plunged by 49.16% to -$42.1 million in 2024, then sank by 45.53% to -$61.3 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$61.3 million, -$55.2 million, and -$42.1 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -61.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -61.27 Mn |
| Apr 30, 2025 | -55.23 Mn |
| Oct 31, 2024 | -42.10 Mn |
| Jul 31, 2024 | -39.82 Mn |
| Apr 30, 2024 | -44.84 Mn |
| Jan 31, 2024 | -28.86 Mn |
| Oct 31, 2023 | -28.22 Mn |
| Jul 31, 2023 | -25.15 Mn |
| Apr 30, 2023 | -25.82 Mn |
| Jan 31, 2023 | -19.52 Mn |
| Oct 31, 2022 | -23.43 Mn |
| Jul 31, 2022 | -23.33 Mn |
| Apr 30, 2022 | -25.64 Mn |
| Jan 31, 2022 | -23.09 Mn |
| Oct 31, 2021 | -19.88 Mn |
| Jul 31, 2021 | -16.17 Mn |
| Apr 30, 2021 | -15.12 Mn |
| Jan 31, 2021 | -9.36 Mn |
| Oct 31, 2020 | -10.76 Mn |
| Jul 31, 2020 | -10.55 Mn |
| Apr 30, 2020 | -7.08 Mn |
| Jan 31, 2020 | -9.21 Mn |
| Oct 31, 2019 | -5.38 Mn |
| Jul 31, 2019 | -7.40 Mn |
| Apr 30, 2019 | -8.35 Mn |
| Jan 31, 2019 | -3.82 Mn |
| Oct 31, 2018 | -3.11 Mn |
| Jul 31, 2018 | -6.35 Mn |
| Apr 30, 2018 | -1.63 Mn |
| Jan 31, 2018 | -2.80 Mn |
| Oct 31, 2017 | -5.03 Mn |
| Jul 31, 2017 | -4.81 Mn |
| Apr 30, 2017 | -3.94 Mn |
| Jan 31, 2017 | -7.48 Mn |
| Oct 31, 2016 | -1.97 Mn |
| Jul 31, 2016 | 885,000.00 |
| Mar 31, 2016 | -6.53 Mn |
| Dec 31, 2015 | -5.57 Mn |
| Sep 30, 2015 | -4.90 Mn |
| Jun 30, 2015 | -5.67 Mn |
| Mar 31, 2015 | -4.90 Mn |
| Sep 30, 2014 | -3.57 Mn |
| Jun 30, 2014 | -2.44 Mn |
| Mar 31, 2014 | -1.86 Mn |